Dr. Ekman has served as a member of the Ultragenyx board since March 2016. He is currently an executive partner at Sofinnova Ventures, a role which he has held since 2008. Dr. Ekman previously served as co-founder and chief executive officer of Cebix Inc, a C-peptide replacement therapy company. Prior to that he served as president of research and development at Elan. Before joining Elan, Dr. Ekman led research and development at Schwarz Pharma AG, and prior to that, he held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer). Dr. Ekman currently serves as chair of the board of Prothena Corporation plc. Dr. Ekman is a board-certified surgeon who has held several clinical and academic positions in the United States and Europe. He earned an M.D. and a Ph.D. in experimental biology from the University of Gothenburg, Sweden.